SEARCH

SEARCH BY CITATION

References

  • 1
    Odorico JS, Pirsch JD, Knechtle SJ, D'Alessandro AM, Sollinger HW. A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation. Transplantation 1998; 66: 17519.
  • 2
    Elkhammas EA, Yilmaz S, Henry ML et al. Simultaneous pancreas/kidney transplantation: comparison of mycophenolate mofetil versus azathioprine. Transplant Proc 1998; 30: 512.
  • 3
    Merion RM, Henry ML, Melzer JS, Sollinger HW, Sutherland DE, Taylor RJ. Randomized, prospective trial of mycophenolate mofetil versus azathioprine for prevention of acute renal allograft rejection after simultaneous kidney-pancreas transplantation. Transplantation 2000; 70: 105111.
  • 4
    Nakache R, Malaise J, Secchi A. Tacrolimus versus cyclosporine in primary simultaneous pancreas-kidney transplantation: six months results of a large multicentre trial. Acta Chir Aust 2001; 33: 8.
  • 5
    Stratta RJ, for the FK506/MMF Multi-Center Study Group. Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multi-center report. Transplant Proc 1997; 29: 654655.
  • 6
    Stegall MD, Simon M, Wachs ME, Chan L, Nolan C, Kam I. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. Transplantation 1997; 64: 16951700.
  • 7
    Gruessner RQG, Sutherland DER, Drangstveit MB, West M, Gruessner AC. Mycophenolate mofetil and tacrolimus for induction and maintenance therapy after pancreas transplantation. Transplant Proc 1998; 30: 518520.
  • 8
    Bruce DS, Woodle ES, Newell KA et al. Tacrolimus/mycophenolate provides superior immunosuppression relative to Neoral/mycophenolate in synchronous pancreas-kidney transplantation. Transplant Proc 1998; 30: 1538– 1540.
  • 9
    Kaufman DB, Leventhal JR, Stuart J, Abecassis MM, Fryer JP, Stuart FP. Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: Initial experience in 50 consecutive cases. Transplantation 1999; 67: 586593.
  • 10
    Helderman JH, Bennett WM, Cibrik DM, Kaufman DB, Klein A, Takemoto SK. Scientific Registry of Transplant Recipients Report on the State of Transplantation: Immunosuppression: Practice and Trends. Am J Transplant 2003; 3(Suppl. 4): 41–52.
  • 11
    Burke GW, Ciancio G, Alejandro R et al. Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction. Transplant Proc 1998; 30: 15441545.
  • 12
    Corry RJ, Shapiro R, Egidi MF et al. Pancreas transplantation without antibody therapy. Transplant Proc 1998; 30: 299300.
  • 13
    Jordan ML, Shapiro R, Gritsch HA et al. Long-term results of pancreas transplantation under tacrolimus immunosuppression. Transplantation 1999; 67: 266272.
  • 14
    Reddy KS, Stratta RJ, Shokouh-Amiri H et al. Simultaneous kidney-pancreas transplantation without antilymphocyte induction. Transplantation 2000; 69: 4954.
  • 15
    Based on data from the International Pancreas Transplant Registry of the Scientific Registry of the United Network for Organ Sharing.
  • 16
    Kaufman DB, Leventhal JR, Gallon LG et al. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kindey transplantation. Transplantation 2001; 72: 19401942.
  • 17
    Stratta RJ, Alloway RR, Hodge E, Lo A, for the PIVOT Study Group. A multicenter, open-label, comparative trial of two daclizumab dosing strategies versus no antibody induction in combination with tacrolimus, mycophenolate mofetil and steroids for the prevention of acute rejection in simultaneous kidney pancreas transplant recipients: interim analysis. Clin Transpl 2002; 16: 6068.